by wilheminamancia | Oct 22, 2023 | Health & Fitness, Alternative Medicine
Although the company will continue to pursue “higher-risk, high reward” drug candidates such as pegilodecakin, these will be a smaller part of the portfolio in the future, said Chief Scientific Officer Daniel Skovronsky.Nicholas Hewlett, head of St...
Recent Comments